This inventor holds 2 USPTO granted patents. Top assignee: Alza Corporation. Active years: 1996.
Company Filing History:
Years Active: 1996
Title: Karly S Wang: Innovator in Bioerodible Devices and Transdermal Adhesives
Introduction
Karly S Wang is a notable inventor based in Newark, CA (US). She has made significant contributions to the field of bioerodible devices and transdermal delivery systems. With a total of 2 patents, her work focuses on improving the delivery of therapeutic agents through innovative materials and methods.
Latest Patents
Karly's latest patents include "Bioerodible devices and compositions for diffusional release of agents" and "Polyisobutylene adhesives for transdermal devices." The first patent addresses the development of erodible delivery devices made from bioerodible polymers. These devices are designed to release active agents at a controlled rate, independent of the polymer's erosion rate. This innovation enhances the control and reproducibility of the release profile of therapeutic agents. The second patent introduces an in-line adhesive for transdermal delivery devices, which utilizes a specific mixture of high and low molecular weight polyisobutylene. This adhesive is particularly effective for delivering oily non-polar agents, such as nicotine and benztropine.
Career Highlights
Karly S Wang is associated with Alza Corporation, where she has been instrumental in advancing drug delivery technologies. Her work has contributed to the development of innovative solutions that improve patient outcomes through effective medication delivery.
Collaborations
Karly has collaborated with notable colleagues, including Wouter E Roorda and Fred P Ehnow. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.
Conclusion
Karly S Wang's contributions to the fields of bioerodible devices and transdermal adhesives highlight her role as a leading inventor. Her patents reflect a commitment to enhancing drug delivery systems, ultimately benefiting patients and the medical community.
